103 related articles for article (PubMed ID: 25489726)
41. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
[TBL] [Abstract][Full Text] [Related]
43. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
[TBL] [Abstract][Full Text] [Related]
44. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
45. [Level of cytokeratin-19 in serum of patients with non small cell lung cancer].
Cynowska B; Słomiński JM; Wyrwiński J
Pneumonol Alergol Pol; 1995; 63(11-12):615-20. PubMed ID: 8616476
[TBL] [Abstract][Full Text] [Related]
46. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
47. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
48. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.
Gao HF; Li AN; Yang JJ; Chen ZH; Xie Z; Zhang XC; Su J; Lou NN; Yan HH; Han JF; Wu YL
Clin Lung Cancer; 2017 Jan; 18(1):85-91. PubMed ID: 27461774
[TBL] [Abstract][Full Text] [Related]
49. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
[TBL] [Abstract][Full Text] [Related]
50. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
[TBL] [Abstract][Full Text] [Related]
51. A comparison of consistency of detecting c-MET gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients.
Chen D; Xu C; Wu J; Zhang Y; Fang M
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C63-7. PubMed ID: 26323927
[TBL] [Abstract][Full Text] [Related]
52. Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction.
Yang YJ; Chen H; Huang P; Li CH; Dong ZH; Hou YL
Clin Invest Med; 2011 Aug; 34(4):E238. PubMed ID: 21810382
[TBL] [Abstract][Full Text] [Related]
53. Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer.
Liang Y; Ma T; Thakur A; Yu H; Gao L; Shi P; Li X; Ren H; Jia L; Zhang S; Li Z; Chen M
Glycobiology; 2015 Mar; 25(3):331-40. PubMed ID: 25347993
[TBL] [Abstract][Full Text] [Related]
54. Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature.
DeCotiis C; Hu Y; Greenberg AK; Huie M; Tsay JC; Pass H; Goldberg JD; Rom WN
Cancer Biomark; 2016; 16(2):219-33. PubMed ID: 26756613
[TBL] [Abstract][Full Text] [Related]
55. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study.
Sozzi G; Roz L; Conte D; Mariani L; Andriani F; Lo Vullo S; Verri C; Pastorino U
Am J Respir Crit Care Med; 2009 Jan; 179(1):69-74. PubMed ID: 18787214
[TBL] [Abstract][Full Text] [Related]
56. [Variation of serum thyroid transcription factor-1 protein and its value in the diagnosis of lung carcinoma].
Li X; Wan LY; Shen H; Bai XY
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1592-6. PubMed ID: 21945775
[TBL] [Abstract][Full Text] [Related]
57. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients.
Hosoda H; Izumi H; Tukada Y; Takagiwa J; Chiaki T; Yano M; Arai H
Ann Thorac Cardiovasc Surg; 2012; 18(1):1-7. PubMed ID: 21959198
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of Annexin A2 as a novel diagnostic serum biomarker for lung cancer.
Yang J; Yang F; Nie J; Zou X; Tian H; Qin Y; Liu C
Cancer Biomark; 2015; 15(2):205-11. PubMed ID: 25519022
[TBL] [Abstract][Full Text] [Related]
59. [Biomarkers in the detection of minimal systemic dissemination in lung cancer patients].
Benedíková A; Srovnal J; Szkorupa M; Skalický P; Chudácek J; Bohanes T; Skarda J; Kolár Z; Hajdúch M; Klein J
Rozhl Chir; 2012 Apr; 91(4):209-15. PubMed ID: 22880268
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis.
Pyo JS; Kang G; Cho WJ; Choi SB
Pathol Res Pract; 2016 Aug; 212(8):710-6. PubMed ID: 27465837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
